Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer.

ABSTRACT:

Importance

Breast cancer treatment can impact not only short-term health but may also affect longer-term quality of life (QOL).

Objective

To describe and evaluate factors associated with diminished QOL following completion of active treatment.

Design, setting, and participants

This was a secondary analysis of a randomized clinical trial included patients with lymph node-positive or high-risk lymph node-negative breast cancer who had undergone definitive surgery and were enrolled in ECOG-ACRIN E5103, a multisite phase 3 trial. A survey was administered 18 months after enrollment to patients enrolled between January and June 2010. Final analysis of the data took place from March to December 2021.

Interventions

Patients received adjuvant doxorubicin, cyclophospham

SUBMITTER: Rosenberg SM 

PROVIDER: S-EPMC8886546 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature